Literature DB >> 28337328

Structure-Activity Relationship Study of QL47: A Broad-Spectrum Antiviral Agent.

Yanke Liang1, Melissanne de Wispelaere2, Margot Carocci2, Qingsong Liu1, Jinhua Wang1, Priscilla L Yang2, Nathanael S Gray1.   

Abstract

Here we report the structure-activity relationship (SAR) investigations of QL-XII-47 (QL47), a compound that possesses broad-spectrum antiviral activity against dengue virus and other RNA viruses. A medicinal chemistry campaign initiated from QL47, a previously reported covalent BTK inhibitor, to derive YKL-04-085, which is devoid of any kinase activity when screened against a panel of 468 kinases and with improved pharmacokinetic properties. Both QL47 and YKL-04-085 are potent inhibitors of viral translation and exhibit cellular antiviral activity at 35-fold lower concentrations relative to inhibition of host-cell proliferation.

Entities:  

Keywords:  Dengue virus; QL47; broad-spectrum antiviral; structure−activity relationship

Year:  2017        PMID: 28337328      PMCID: PMC5346993          DOI: 10.1021/acsmedchemlett.7b00008

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  29 in total

1.  Phylogeny of the genus Flavivirus.

Authors:  G Kuno; G J Chang; K R Tsuchiya; N Karabatsos; C B Cropp
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

Review 2.  Direct-acting antiviral agents for hepatitis C virus infection.

Authors:  Jennifer J Kiser; Charles Flexner
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-11-05       Impact factor: 13.820

3.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

Review 4.  HIV-1 protease inhibitors. A review for clinicians.

Authors:  S G Deeks; M Smith; M Holodniy; J O Kahn
Journal:  JAMA       Date:  1997-01-08       Impact factor: 56.272

5.  Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.

Authors:  Wooyoung Hur; Anastasia Velentza; Sungjoon Kim; Laura Flatauer; Xinnong Jiang; David Valente; Daniel E Mason; Melissa Suzuki; Brad Larson; Jianming Zhang; Anna Zagorska; Michael Didonato; Advait Nagle; Markus Warmuth; Steven P Balk; Eric C Peters; Nathanael S Gray
Journal:  Bioorg Med Chem Lett       Date:  2008-07-18       Impact factor: 2.823

6.  Development of Selective Covalent Janus Kinase 3 Inhibitors.

Authors:  Li Tan; Koshi Akahane; Randall McNally; Kathleen M S E Reyskens; Scott B Ficarro; Suhu Liu; Grit S Herter-Sprie; Shohei Koyama; Michael J Pattison; Katherine Labella; Liv Johannessen; Esra A Akbay; Kwok-Kin Wong; David A Frank; Jarrod A Marto; Thomas A Look; J Simon C Arthur; Michael J Eck; Nathanael S Gray
Journal:  J Med Chem       Date:  2015-08-18       Impact factor: 7.446

7.  c-Src protein kinase inhibitors block assembly and maturation of dengue virus.

Authors:  J J H Chu; Priscilla L Yang
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-21       Impact factor: 11.205

8.  Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.

Authors:  Wenjun Zhou; Dalia Ercan; Liang Chen; Cai-Hong Yun; Danan Li; Marzia Capelletti; Alexis B Cortot; Lucian Chirieac; Roxana E Iacob; Robert Padera; John R Engen; Kwok-Kin Wong; Michael J Eck; Nathanael S Gray; Pasi A Jänne
Journal:  Nature       Date:  2009-12-24       Impact factor: 49.962

Review 9.  Systems biology and the host response to viral infection.

Authors:  Seng-Lai Tan; Gopinath Ganji; Bryan Paeper; Sean Proll; Michael G Katze
Journal:  Nat Biotechnol       Date:  2007-12       Impact factor: 54.908

10.  Discovery of a potent, covalent BTK inhibitor for B-cell lymphoma.

Authors:  Hong Wu; Wenchao Wang; Feiyang Liu; Ellen L Weisberg; Bei Tian; Yongfei Chen; Binhua Li; Aoli Wang; Beilei Wang; Zheng Zhao; Douglas W McMillin; Chen Hu; Hong Li; Jinhua Wang; Yanke Liang; Sara J Buhrlage; Junting Liang; Jing Liu; Guang Yang; Jennifer R Brown; Steven P Treon; Constantine S Mitsiades; James D Griffin; Qingsong Liu; Nathanael S Gray
Journal:  ACS Chem Biol       Date:  2014-03-17       Impact factor: 5.100

View more
  5 in total

1.  Covalent Antiviral Agents.

Authors:  Sako Mirzaie; Fatemeh Abdi; Amin GhavamiNejad; Brian Lu; Xiao Yu Wu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Contemporary Strategies and Current Trends in Designing Antiviral Drugs against Dengue Fever via Targeting Host-Based Approaches.

Authors:  Foysal Ahammad; Tengku Rogayah Tengku Abd Rashid; Maizan Mohamed; Suriyea Tanbin; Fazia Adyani Ahmad Fuad
Journal:  Microorganisms       Date:  2019-08-28

3.  A broad-spectrum antiviral molecule, QL47, selectively inhibits eukaryotic translation.

Authors:  Mélissanne de Wispelaere; Margot Carocci; Dominique J Burri; William J Neidermyer; Calla M Olson; Imme Roggenbach; Yanke Liang; Jinhua Wang; Sean P J Whelan; Nathanael S Gray; Priscilla L Yang
Journal:  J Biol Chem       Date:  2019-12-30       Impact factor: 5.157

Review 4.  Synthetic and medicinal perspective of quinolines as antiviral agents.

Authors:  Ramandeep Kaur; Kapil Kumar
Journal:  Eur J Med Chem       Date:  2021-01-24       Impact factor: 6.514

5.  Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia.

Authors:  Chen Hu; Fengming Zou; Aoli Wang; Weili Miao; Qianmao Liang; Ellen L Weisberg; Yinsheng Wang; Jing Liu; Wenchao Wang; Qingsong Liu
Journal:  Signal Transduct Target Ther       Date:  2021-09-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.